Author

Juozas Kupcinskas

THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)
THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)

Juozas Kupcinskas  et al.

GASTRIC CANCER MUCOSAL MICROBIOME IS ASSOCIATED WITH PROGNOSIS OF GASTRIC CANCER PATIENTS
GASTRIC CANCER MUCOSAL MICROBIOME IS ASSOCIATED WITH PROGNOSIS OF GASTRIC CANCER PATIENTS

Juozas Kupcinskas  et al.

EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS
MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS

Juozas Kupcinskas  et al.

EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES
EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Juozas Kupcinskas  et al.

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Juozas Kupcinskas  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Juozas Kupcinskas  et al.

FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)
FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Juozas Kupcinskas  et al.

THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY
THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY

Juozas Kupcinskas  et al.

TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Juozas Kupcinskas  et al.

CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Juozas Kupcinskas  et al.

Item 21 - 36 / 36
1
2